Icad 8-K 2010
ICAD REPORTS FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Conference Call to be Held Tuesday, February 23rd at 10:00 a.m. Eastern Time
NASHUA, N.H. (February 22, 2010) iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today reported financial results for the three and twelve months ended December 31, 2009.
Financial highlights for the fourth quarter of 2009 include the following (all comparisons are with the fourth quarter of 2008):
Financial highlights for fiscal year 2009 include the following (all comparisons are with fiscal year 2008):
We are pleased with our fourth quarter performance and sustained profitability throughout the second half of the year as well as generating positive cash flow in the face of macroeconomic challenges. Our confidence as we enter 2010 is supported by two quarters of sequential revenue growth, the strongest balance sheet in iCADs history, a highly competitive and broader product line, and prospects of a strengthening economy. We believe iCAD is well-positioned to capitalize on the continuing growth resulting from the transition from film-based to digital technology in the mammography market, and in the ongoing need for more advanced image analysis and workflow solutions to improve the diagnosis and treatment paradigms for leading cancers, commented Ken Ferry, president and CEO of iCAD.
iCAD hosted a number of important meetings focused on CAD and other advanced image analysis solutions for the early detection of cancer at this years annual meeting of the Radiological Society of North America (RSNA). The RSNA was a very successful event for iCAD as we showcased our technologies and held educational initiatives on incorporating image analysis and workflow improvements into hospitals and free-standing imaging centers. Our oversubscribed symposium highlighted how quantitative image analysis and MRI play an integral role in prostate cancer programs including pre-biopsy guidance, treatment planning, active surveillance and therapy response monitoring.
We remain encouraged by the significant opportunities for CAD to enhance prostate cancer early detection and treatment. Toward that end, we were delighted to partner with AdMeTech, a non-profit organization with a mission to end prostate cancer as a patient care crisis and socio-economic problem, and with a goal to advance research, education and public awareness to improve the diagnostic paradigm for prostate care. A significant step towards achieving this goal is to secure MRI as a standard of care in diagnosis for the patients who undergo approximately 1.2 million prostate biopsies each year in the U.S., concluded Ferry.
Fourth Quarter Results
Total revenue for the fourth quarter of 2009 was $8.1 million, a decrease of 13% compared with $9.3 million for the fourth quarter of 2008. This reflects a 12% decline in revenue from the Companys digital and MRI CAD products to $5.6 million from $6.3 million in the prior year, as purchases of capital equipment by U.S. hospitals remained soft comparatively and were somewhat offset by purchases of the Companys newer MRI CAD products. International revenue increased 42% to $948,000 from $669,000 in the fourth quarter of 2008.
Total film-based revenue for the fourth quarter of 2009 declined to $1.2 million from $2.2 million in the fourth quarter of 2008. The decline in film based revenue can also be attributed to the softer demand for digital mammography as the majority of film based revenue is derived from sales of the TotalLook MammoAdvantage, a digitizing and comparative reading solution that is sold to further optimize workflow in a digital mammography environment.
Service and supply revenue increased 59% to $1.3 million from $798,000 in the prior year, primarily due to growth in service contract revenue as digital CAD and TotalLook MammoAdvantage systems continue to transition from warranty to service contracts, underscoring the growth in the Companys installed product base.
The Company maintained a record gross margin of 84.8% for the fourth quarter of 2009 compared with 83.7% in the prior-year fourth quarter, primarily due to optimized pricing and cost management. Fourth quarter 2009 operating expenses decreased to $6.6 million from $7.5 million or 12% reported in the fourth quarter of 2008, due primarily to reduced clinical trial expense associated with the completion of the Companys colon CAD reader study, marketing and trade show expenses, compensation related expense, travel expenses and depreciation and amortization expenses, offset by increased professional fees. For the fourth quarter of 2009 the Company posted net income, including stock-based compensation expense of $499,000, of $317,000 or $0.01 per diluted share, compared with net income, including stock-based compensation expense of $508,000, of $321,000 or $0.01 per diluted share in the fourth quarter of 2008.
Full Year Results
Total revenue for fiscal year 2009 was $28.1 million, down 25% from $37.5 million for fiscal year 2008. The gross margin for 2009 increased slightly to 83.6% from 83.5% in 2008. The net loss for 2009, including stock-based compensation expense of $2.0 million, was $2.0 million or ($0.04) per share, compared with net income, including stock-based compensation expense of $1.9 million, of $4.4 million or $0.10 per diluted share for 2008.
Sales of iCADs digital and MRI CAD solutions in 2009 decreased 32% compared to 2008 to $18.3 million from $26.7 million. Sales of film-based products of $5.8 million decreased 22% from $7.4 million during 2008. Service and supply revenue in 2009 increased 21% to $4.0 million from $3.3 million in 2008. International revenue for 2009 increased 26% to $3.7 million, compared with $2.9 million in 2008, and represented 13% of total revenue for the year.
As of December 31, 2009, iCAD had cash and cash equivalents of $16.2 million, compared with $13.1 million as of December 31, 2008.
Darlene Deptula-Hicks, executive vice president and CFO, said, We significantly strengthened our balance sheet throughout 2009 and were pleased to end the year with the strongest cash position in the Companys history. Disciplined fiscal management is evidenced in improvements on all financial metrics relevant to building a solid and sustainable company, including a 24% reduction in inventory, a 38% reduction in accounts payable and an 80% increase in deferred revenue compared with 2008. As a result, we believe iCAD is well-positioned to benefit from improving market conditions.
2010 Financial Guidance
While iCAD management is becoming increasingly optimistic about the Companys prospects in 2010, due to the economic environment and associated uncertainty in the healthcare markets iCAD serves, the Company has made a decision to defer providing financial guidance at this time. This decision will be reviewed mid-year and iCAD will provide an update at that time.
iCAD management will host an investment community conference call beginning at 10:00 a.m. Eastern time on Tuesday, February 23, 2010 to discuss these results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 866-356-4279 (domestic) or 617-597-5394 (international) and entering passcode 61887390. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.
A replay of the conference call will be available beginning two hours after its completion through March 2, 2010 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 72811143. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Since receiving FDA approval for the Companys first breast cancer detection product in 2002, more than 3,200 iCAD systems have been placed in healthcare practices worldwide. iCADs solutions aid in the early detection of the most prevalent cancers including breast and prostate, and in the future colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.
For iCAD, contact Darlene Deptula-Hicks, EVP and CFO at 603-882-5200 x7944 or
via email at email@example.com
For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at
212-838-3777 x6604 or via email at firstname.lastname@example.org
For iCAD Public Relations, contact Liza Heapes of MS&L
at 617-369-8787 or via e-mail at email@example.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release, including but not limited to, statements about the Companys confidence or strategies or expectations about revenues, results of operations, timing of regulatory approval of
products or market opportunities, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Companys filings with the Securities and Exchange Commission. The words believe, demonstrate, intend, expect, estimate, anticipate, likely, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
-Tables to Follow-
Consolidated Statements of Operations
Consolidated Balance Sheets
# # #